Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO2006098394 - METHOD FOR INHIBITING LIPID ABSORPTION AND LIPID ABSORPTION INHIBITOR

Publication Number WO/2006/098394
Publication Date 21.09.2006
International Application No. PCT/JP2006/305188
International Filing Date 09.03.2006
IPC
A61K 45/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A61K 31/21 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
A61K 31/41 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 31/47 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
A61P 3/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
04Anorexiants; Antiobesity agents
A61P 3/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
06Antihyperlipidemics
CPC
A61K 31/165
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
A61K 31/325
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
A61K 31/41
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
A61K 31/445
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
A61K 31/47
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
Applicants
  • 日本たばこ産業株式会社 JAPAN TOBACCO INC. [JP]/[JP] (AllExceptUS)
  • 米森 文彦 YONEMORI, Fumihiko [JP]/[JP] (UsOnly)
  • 高橋 大祐 TAKAHASHI, Daisuke [JP]/[JP] (UsOnly)
  • 古川 昇 FURUKAWA, Noboru [JP]/[JP] (UsOnly)
Inventors
  • 米森 文彦 YONEMORI, Fumihiko
  • 高橋 大祐 TAKAHASHI, Daisuke
  • 古川 昇 FURUKAWA, Noboru
Agents
  • 大東 輝雄 DAITO, Teruo
Priority Data
2005-07029214.03.2005JP
60/666,25229.03.2005US
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) METHOD FOR INHIBITING LIPID ABSORPTION AND LIPID ABSORPTION INHIBITOR
(FR) MÉTHODE POUR INHIBER L’ABSORPTION DE LIPIDES ET L’INHIBITEUR DE L'ABSORPTION DE LIPIDES
(JA) 脂質吸収抑制方法および脂質吸収抑制剤
Abstract
(EN)
The invention relates to a method for inhibiting lipid absorption from the small intestine comprising administering a compound having a CETP inhibitory effect to a subject to be administered and an inhibitor of lipid absorption from the small intestine characterized by comprising a compound having a CETP inhibitory effect as an active ingredient. The lipid absorption inhibitor of the invention can prevent and/or treat a disease such as hyperlipemia, arteriosclerosis, a coronary artery disease, obesity, diabetes, hypertension and metabolic syndrome by inhibiting lipid absorption from the small intestine.
(FR)
L'invention concerne une méthode pour inhiber l'absorption de lipides par l'intestin grêle comprenant l’administration d’un composé ayant un effet inhibiteur sur la protéine de transfert CETP chez un sujet à qui on l’administre, et un inhibiteur de l'absorption de lipides par l'intestin grêle caractérisé en ce qu’il contient comme principe actif un composé ayant un effet inhibiteur sur la CETP. L'inhibiteur de l'absorption de lipides de l'invention peut prévenir et/ou traiter une maladie tel que hyperlipémie, artériosclérose, une maladie des artères coronaires, obésité, diabète, hypertension et syndrome métabolique en inhibant l'absorption de lipides par l'intestin grêle.
(JA)
本発明は、CETP阻害作用を有する化合物を投与対象に投与することを含む、小腸からの脂質吸収抑制方法ならびにCETP阻害作用を有する化合物を有効成分として含有することを特徴とする小腸からの脂質吸収抑制剤に関する。本発明の脂質吸収抑制剤は、小腸からの脂質吸収を抑制することにより、例えば、高脂血症、動脈硬化症、冠動脈疾患、肥満症、糖尿病、高血圧症、メタボリックシンドロームなどの疾患の予防および/または治療が可能である。
Also published as
EP6715679
Latest bibliographic data on file with the International Bureau